Algúns fármacos agonistas serotoninérxicos tamén causan fibrose en calquera parte do corpo, especialmente na síndrome de [[fibrose retroperitoneal]], e na [[fibrose cardíaca|fibrose de válvula cardíaca]].<ref name="Baskin">{{cita libro|autor = Baskin SI|título = Principles of cardiac toxicology|editorial = CRC Press|location = Boca Raton|ano = 1991|isbn = 0-8493-8809-0|url = http://books.google.com/?id=AW7M6jBixj4C&pg=PA626|accessdate = 2010-02-03}}</ref>
No pasado, foron asociados epidemioloxicamente con estas síndromes tres grupos de fármacos serotonérxicos. Son os fármacos antimigrañas vasoconstritores serotoninérxicos ([[ergotamina]] e ''[[methysergide]]''),<ref name=Baskin/> os fármacos supresores do apetito serotoninérxicos ([[fenfluramina]], [[clorfentermina]], e [[aminorex]]), e certos agonistas dopaminérxicos anti-Parkinsonianos, os cales tamén estimulan os receptores 5-HT<sub>2B</sub> serotoninérxicos. Estes inclúen o ''[[pergolide]]'' e o ''[[cabergoline]]'', pero non o específico da dopamina ''[[lisuride]]''.<ref name="urluserpage.fu-berlin.de">{{Cita web|url = http://userpage.fu-berlin.de/~hpertz/Presentation001.pdf|title = Pergolide and Cabergoline But not Lisuride Exhibit Agonist Efficacy at Serotonin 5-HT<sub>2B</sub> Receptors|author = Jähnichen S, Horowski R, Pertz H|accessdate = 2010-02-03}}</ref>
Igual que a fenfluramina, algunhas destas drogas (por exemplo o ''pergolide'') foron retiradas do mercado debido aos seus efectos secundarios.<ref name="ADRAC_2004">{{Cita publicación periódica|url = http://www.tga.gov.au/adr/aadrb/aadr0408.htm|year = 2004|title = Cardiac valvulopathy with pergolide|author = ADRAC|journal = Aust Adv Drug React Bull|volume = 23|issue = 4|authorlink = Adverse Drug Reactions Advisory Committee|apelidos = |data = |revista = |data-acceso = 05 de abril de 2012|urlarquivo = https://web.archive.org/web/20120627200919/http://www.tga.gov.au/adr/aadrb/aadr0408.htm|dataarquivo = 27 de xuño de 2012|urlmorta = si}} [http://www.tga.gov.au/adr/aadrb/aadr0408.htm Free full text] {{Webarchive|url=https://web.archive.org/web/20120627200919/http://www.tga.gov.au/adr/aadrb/aadr0408.htm |date=27 de xuño de 2012 }} from the [[Australia]]n [[Therapeutic Goods Administration]]</ref><ref name="pmid17202453">{{Cita publicación periódica|author = Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E|title = Dopamine agonists and the risk of cardiac-valve regurgitation|journal = N. Engl. J. Med.|volume = 356|issue = 1|pages = 29–38|year = 2007|pmid = 17202453|doi = 10.1056/NEJMoa062222}}</ref><ref name="pmid17202454">{{Cita publicación periódica|author = Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G|title = Valvular heart disease and the use of dopamine agonists for Parkinson's disease|journal = N. Engl. J. Med.|volume = 356|issue = 1|pages = 39–46|year = 2007|pmid = 17202454|doi = 10.1056/NEJMoa054830}}</ref><ref>{{Cita web |url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152695.htm |title=Food and Drug Administration Public Health Advisory |date=2007-03-29 |accessdate=2010-02-07}}</ref> Algunhas como ''cabergoline'', que en EEUU só está aprobado o seu uso para a hiperprolactinemia (non para o [[párkinson]]), seguen no mercado porque se usan a baixas doses ás que teñen un risco baixo de producir enfermidades nas válvulas cardíacas.<ref name="FDAwithdraw">{{Cita web|url = http://www.fda.gov/medwatch/safety/2007/safety07.htm#Pergolide|title = MedWatch – 2007 Safety Information Alerts. Permax (pergolide) and generic equivalents|publisher = U.S. [[Food and Drug Administration]]|date = March 29, 2007|accessdate = 2007-03-30}}</ref>
==== Efectos locais da súa inxección: velenos e dor ====
